The goal of this clinical research study is to find the highest tolerable dose of the
combination of Revlimid (lenalidomide) and high-dose Alkeran (melphalan) that can be given to
patients with multiple myeloma who will receive an autologous stem cell transplantation. The
safety of this combination therapy will also be studied.